The authors discuss multiple neurotransmitters in the context of breast cancer as well as the risk factors, repurposing of pharmaceuticals impacting neurotransmitter pathways, and the opportunity for better integrated models that encompass exercise, the intestinal microbiome, and other non-pharmacologic considerations.
[Oncogene]